Looking Back at Chart From 2008 – Why Markets Will Crash – This may happen before the end of this month, or end of this year, possibly Q1, 2016, but it’s almost certain that markets will crash due to lax…
Bearish Free Articles
Updated And Amended: Why Mannkind’s Afrezza Is No Blockbuster And Will Be Rejected By FDA
Updated 6/22: Cleaned up thesis to include that we feel the stock price will tank hard even if Afrezza is approved. Background and Story of Afreza MannKind Corporation (MNKD) is a biopharmaceutical company that focuses on the discovery, development, and…
Did Pozen Mislead Investors Concerning Its Recent FDA Rejection?
On Friday of last week, Pozen Inc.(POZN), received a CRL from the FDA, disallowing the New Drug Application (NDA) for its coordinated-delivery tablet combination of omeprazole (Prilosec) and aspirin. This combination can basically be purchased over the counter (OTC) by…
Keryx Pharma Is Overvalued By At Least 20%
Although we generally look for long plays in the biotechnology sector, certain macroeconomic factors can force us and other investors to look for short ideas. Currently, it’s growing more apparent that money has been shifting, moving out of the pharmaceutical…
